NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CYCN

Cyclerion Therapeutics Inc

Jun 30 • 04:00PM ET

2.91

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT BMRN EXEL BLUE NBIX TBPH CRBP VKTX RDUS PRQR

| Held by: VXF ONEQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.16	Insider Own	39.54%	Shs Outstand	3.06M	Perf Week	1.04%
Market Cap	9.34M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.94M	Perf Month	5.05%
Enterprise Value	5.70M	PEG	-	EPS next Q	-	Inst Own	8.53%	Short Float	1.67%	Perf Quarter	13.23%
Income	-2.94M	P/S	4.49	EPS this Y	-	Inst Trans	34.55%	Short Ratio	1.77	Perf Half Y	-11.55%
Sales	2.08M	P/B	1.01	EPS next Y	-	ROA	-27.76%	Short Interest	0.03M	Perf YTD	-9.63%
Book/sh	2.87	P/C	2.57	EPS next 5Y	-	ROE	-31.48%	52W High	9.47 -69.27%	Perf Year	1.39%
Cash/sh	1.13	P/FCF	-	EPS past 3/5Y	64.17% 57.72%	ROIC	-33.53%	52W Low	1.27 129.13%	Perf 3Y	-75.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-20.24% -15.00%	Gross Margin	0.00%	Volatility	11.60% 8.52%	Perf 5Y	-96.34%
Dividend TTM	-	EV/Sales	2.74	EPS Y/Y TTM	82.09%	Oper. Margin	-166.60%	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.21	Sales Y/Y TTM	-68.09%	Profit Margin	-141.47%	RSI (14)	45.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.21	EPS Q/Q	9.57%	SMA20	-4.60%	Beta	1.55	Target Price	80.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.55%	Rel Volume	0.00	Prev Close	2.91
Employees	1	LT Debt/Eq	0.00	Earnings	-	SMA200	0.05%	Avg Volume	18.23K	Price	2.91
IPO	Mar 18, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-3.33% -13.92%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-21	Initiated	Truist	Buy	$14
Sep-24-21	Initiated	Cantor Fitzgerald	Overweight	$7
Jun-03-19	Initiated	Credit Suisse	Neutral

Dec-17-24 08:08AM	Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth (GlobeNewswire) -7.08%
Aug-07-24 07:00AM	Regina Graul, Ph.D., Promoted to Chief Executive Officer (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +17.98%
May-08-24 08:52AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-05-24 06:53AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 (InvestorPlace)
03:54PM	Loading…
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Dec-04-23 08:00AM	Cyclerion Appoints Regina Graul, Ph.D., as President (GlobeNewswire) -8.71%
Nov-30-23 06:16PM	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator (GlobeNewswire) +7.39% +14.06%
Aug-02-23 08:39PM	The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets (American City Business Journals)
Jul-31-23 07:00AM	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets (GlobeNewswire) +14.15%
Jun-01-23 04:00PM	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-15-23 01:00PM	Cyclerion Announces Reverse Stock Split (GlobeNewswire) -14.34%
May-12-23 02:59PM	Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors (Benzinga) -25.10%
May-11-23 06:00PM	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 (GlobeNewswire)
06:00PM	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results (GlobeNewswire)
07:30AM	Loading…
Apr-03-23 07:30AM	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement (GlobeNewswire) -17.98%
Mar-27-23 07:00AM	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases (GlobeNewswire) +23.71%
Mar-22-23 04:40PM	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results (GlobeNewswire) -11.54%
Nov-22-22 07:00AM	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company (GlobeNewswire) +34.31%
Nov-09-22 06:34AM	Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) (Simply Wall St.)
Oct-07-22 02:31PM	Cyclerion Therapeutics lays off nearly half of workforce (American City Business Journals) -9.66%
Oct-06-22 12:46PM	Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction (Benzinga) -37.57%
08:00AM	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy (GlobeNewswire)
Aug-09-22 05:35PM	Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -17.39%
04:00PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 09:22AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? (Simply Wall St.) +27.76%
Jul-28-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) (GlobeNewswire) +22.08%
Jul-26-22 07:00AM	Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics Board of Directors (GlobeNewswire)
Jun-28-22 09:00AM	Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire) -5.55%
Jun-22-22 08:30AM	Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire)
11:20AM	Loading…
Jun-17-22 11:20AM	Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies (Benzinga)
08:00AM	Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease (GlobeNewswire)
Jun-10-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) -20.18%
Jun-06-22 07:00AM	Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) +8.58%
May-11-22 09:30AM	As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year (Simply Wall St.) -8.17%
May-04-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results (GlobeNewswire) +8.62% -5.39%
Feb-27-22 06:39AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-24-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates (GlobeNewswire)
Feb-23-22 08:00AM	Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration (GlobeNewswire)
Feb-01-22 05:30AM	CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board (GlobeNewswire) +9.09%
Jan-26-22 08:00AM	Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimers Disease with Vascular Pathology (GlobeNewswire)
Dec-15-21 10:00AM	Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN) (Zacks) +9.38%
Nov-25-21 04:47AM	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year (Simply Wall St.)
Nov-11-21 05:32PM	Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Nov-09-21 04:01PM	Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -5.42%
Nov-08-21 12:00PM	Exclusive: Startup raises $27M to find brain-based biomarkers (American City Business Journals)
Oct-20-21 04:24PM	Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside (Benzinga) +10.90% -5.42%
Oct-11-21 03:34AM	David Greenspans Slate Path Capital is Buying Coinbase, Stitch Fix, and More (Insider Monkey)
Oct-10-21 09:37AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Sep-22-21 08:00AM	Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator (GlobeNewswire)
Sep-08-21 08:00AM	Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-21 07:19AM	Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-23-21 05:00PM	Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit (GlobeNewswire) +8.16%
Jul-29-21 05:00PM	Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -12.54%
Jul-22-21 04:30PM	Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimers Disease with Vascular Pathology at the Alzheimers Association International Conference 2021 (AAIC) (GlobeNewswire) +14.72%
Jul-12-21 02:24AM	Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares (Simply Wall St.)
Jul-09-21 06:14AM	Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers (Benzinga)
Jul-08-21 07:22PM	Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership (PR Newswire)
04:30PM	Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership (GlobeNewswire)
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise (Benzinga)
08:00AM	Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat (GlobeNewswire)
08:00AM	Cyclerion Therapeutics Announces $18 Million Private Placement (GlobeNewswire)
May-27-21 04:30PM	Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology (GlobeNewswire) +5.25%
May-25-21 07:00AM	Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:36AM	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares (Simply Wall St.)
Apr-27-21 09:00AM	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress (GlobeNewswire) -17.95%
Apr-26-21 07:00AM	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors (GlobeNewswire) +7.22%
Apr-21-21 07:30AM	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference (GlobeNewswire) +5.75%
Apr-20-21 07:00AM	Cyclerion Therapeutics to Host Pipeline Update Webinar (GlobeNewswire) +7.41%
Mar-24-21 04:05PM	TransMedics Appoints Stephanie Lovell to Board of Directors (PR Newswire) -6.80% +5.78%
Mar-22-21 02:23AM	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? (Simply Wall St.)
Mar-19-21 07:46AM	The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs (Benzinga)
Mar-18-21 05:00PM	Cyclerion Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Feb-25-21 07:00AM	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -9.48%
Jan-25-21 07:00AM	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards (GlobeNewswire)
Jan-21-21 12:52AM	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? (Simply Wall St.)
Jan-04-21 07:00AM	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-20 07:30AM	Cyclerion Announces Leadership Transitions (GlobeNewswire)
Dec-02-20 11:27PM	Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy? (Insider Monkey)
Nov-15-20 07:55AM	Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares (Simply Wall St.)
Nov-05-20 07:00AM	Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-20 01:09PM	Why Cyclerion Therapeutics Is Crashing Today (Motley Fool) -52.95%
10:07AM	Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study (Benzinga)
07:00AM	Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects (GlobeNewswire)
07:00AM	Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease (GlobeNewswire)
Oct-04-20 09:52AM	Health Check: How Prudently Does Cyclerion Therapeutics (NASDAQ:CYCN) Use Debt? (Simply Wall St.)
Sep-04-20 07:00AM	Cyclerion to Participate at Upcoming September 2020 Investor Conferences (GlobeNewswire)
Aug-25-20 07:00AM	Cyclerion Announces Translational Research Award from the Alzheimers Association Part the Cloud-Gates Partnership Grant Program (GlobeNewswire) +11.09%
Aug-20-20 11:01AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Aug-03-20 09:25AM	Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.81%
Jul-30-20 09:00AM	Cyclerion Therapeutics Completes $24 Million Private Placement (GlobeNewswire) +12.50%
Jul-17-20 07:00AM	Cyclerion Therapeutics Presentation at Biomarkers in Alzheimers Disease Summit (GlobeNewswire)
Jul-06-20 03:17PM	We're A Little Worried About Cyclerion Therapeutics's (NASDAQ:CYCN) Cash Burn Rate (Simply Wall St.)
Jul-05-20 02:45PM	Should You Buy Cyclerion Therapeutics, Inc. (CYCN)? (Insider Monkey)
Jun-18-20 04:01PM	Cyclerion to Host Webcast Investor Event on July 9, 2020 (GlobeNewswire) +18.04%
May-22-20 07:52AM	The Cyclerion Therapeutics (NASDAQ:CYCN) Share Price Is Down 72% So Some Shareholders Are Rather Upset (Simply Wall St.) +6.45%
Apr-10-20 07:00AM	Cyclerion Updates Corporate Progress (GlobeNewswire)
Mar-23-20 06:50AM	Are Insiders Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock? (Simply Wall St.) +18.94%
Jan-13-20 07:00AM	Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases (GlobeNewswire) +10.26%
Jan-12-20 05:05PM	The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO (Benzinga)

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Slate Path Capital LP	10% Owner	Nov 21 '24	Sale	1.55	357,880	555,108	0	Nov 25 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYCN

Cyclerion Therapeutics Inc

Upgrade your FINVIZ experience